Skip to main content
. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437

Figure 7.

Figure 7.

Composite predictive biomarkers are enriched in the ALK-positive lung cancer group. Various composite predictive biomarkers profiles of clinical response to blockade of the PD-1-PD-L1 pathway were defined based on criteria from the literature. Four composite biomarkers were presented. (A) PDL-1+ on tumor cells > 10% and intratumoral (intraT) CD8+ T cells > median (med). (B) PDL-1+ on tumor cells > 10% and intratumoral PD-1+CD8+ T cells > median. (C) PDL-1+ on tumor cells > 10% and intratumoral PD-1+CD8+ T cells > median and b2-microglobulin > median. (D) PD-L1+ on tumor cells > 10% and PD-L1+ stromal/immune cells (IC)) > median and intratumoral PD-1+CD8+ T cells > median. The percentage of each subgroup of lung cancer patients (ALK-positive, EGFR- mutated, non-EGFR-mutated and non-KRAS-mutated and non-ALK-positive tumors) or after dichotomization between ALK-positive and non-ALK-positive tumors displaying these composite predictive biomarker is shown. The proportion of patients with composite biomarkers were compared between subgroups using Fisher's exact test.